Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease.

Next Previous
X
Search
Trial Profile

A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease; Dyspnoea
  • Focus Registrational; Therapeutic Use
  • Acronyms GLOW-1
  • Sponsors Novartis

    • Most Recent Events

    • 02 May 2024 According to Kodiak media release,data from this study will be presented at Association for Research in Vision and Ophthalmology 2024 Annual Meeting, being held from May 5-9 in Seattle, Washington.
    • 23 Oct 2012 Planned number of patients changed from 800 to 1230.
    • 05 Sep 2012 Results from a pooled analysis of GLOW 1 and GLOW 2 presented at the 22nd Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top